Seraxis is a privately held biotechnology company with operations located in the BioHealth Capital Region, Maryland. Seraxis proprietary transplant ready islets and device were developed in house. Seraxis is advancing its cell therapy/device combination, SR-01 to the clinic.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/10/21 | $40,000,000 | Series C |
Eli Lilly and Company Frazier Healthcare Partners JDRF T1D Fund Polaris Ventures | undisclosed |
